FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
LL-37 5mg research peptide vial
Immune

LL-37

Cathelicidin fragment

A host-defense peptide studied in antimicrobial and immune research.

$90

In stock · ships in 1–2 business days

  • ✓ ≥98.5% purity
  • ✓ HPLC + mass-spec tested
  • ✓ Batch COA available
  • ✓ Discreet US shipping
antimicrobial researchimmune

Research Summary

LL-37 is a human cathelicidin-derived antimicrobial peptide studied in preclinical research for host-defense, immune-modulation, and wound-microenvironment models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

LL-37: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is LL-37?

LL-37 is a 37-amino-acid peptide named for its first two residues (two leucines) and its length. It is the only cathelicidin-derived antimicrobial peptide found in humans [3]. Its sequence and formula are recorded in PubChem [1]. It forms the C-terminal end of a larger precursor protein, the human cathelicidin antimicrobial peptide (CAMP, also called hCAP-18), corresponding to residues 134 to 170 of that protein [2].

A 2006 review described LL-37 as an amphipathic, helical peptide expressed in epithelial cells of the skin, gastrointestinal tract, respiratory tract, and testis, and in white blood cells including neutrophils, monocytes, and lymphocytes [3]. Beyond killing microbes, it has been studied for its effects on inflammation, immune-cell recruitment, endotoxin (LPS) binding, and re-epithelialization in wound models [3].

LL-37 is one of the more thoroughly characterized human host-defense peptides, with structural, cell, and animal studies from many independent groups, along with a small number of clinical trials of a topical formulation. It is also notable for findings in both protective and harmful directions, which this page covers alongside each other.

LL-37 molecular identity
SequenceLeu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
Length37 amino acids
Molecular formulaC205H340N60O53
Molecular weight4493 g/mol
CAS number154947-66-7
PubChem CID16198951
Source proteinHuman cathelicidin antimicrobial peptide (CAMP, hCAP-18), residues 134-170 (UniProt P49913)
Other namesCathelicidin LL-37, ropocamptide (INN), CAP-18 fragment (PubChem synonyms)

Mechanisms studied

Release from its precursor

In a 2001 study of human neutrophils, hCAP-18 was stored intact inside the cell and was not cleaved after phagocytosis. In exocytosed material, however, it was cleaved to generate LL-37, and of the three serine proteases tested from azurophil granules, proteinase 3 alone was responsible [4].

Structure and membrane interaction

A 2008 NMR study determined the structure of LL-37 in detergent micelles as a curved amphipathic helix-bend-helix spanning residues 2 to 31, followed by a disordered C-terminal tail, with the bend located between Gly-14 and Glu-16. The same study identified KR-12, corresponding to residues 18 to 29, as the smallest fragment with antibacterial activity, and reported that it was selectively toxic to bacteria but not human cells in its assays [5].

Regulation by vitamin D

A 2004 study found that the promoter of the human cathelicidin gene contains a vitamin D response element, and that the hormonal form of vitamin D directly induced cathelicidin expression in isolated human keratinocytes, monocytes, neutrophils, and cell lines [9]. A 2005 study extended this to myeloid cells and bone-marrow-derived macrophages, and found that the vitamin D response element sits in a short interspersed nuclear element conserved in primates but absent from the mouse, rat, and dog genomes. Vitamin D did not induce the gene in mouse cells [17]. This link makes vitamin D signaling a common variable in LL-37 research, and it is one reason rodent findings may not map directly onto human cathelicidin biology.

Receptor signaling in endothelial cells

A 2003 study attributed angiogenic effects of LL-37 to formyl peptide receptor-like 1 on endothelial cells. LL-37 increased endothelial proliferation and vessel-like structure formation in culture and produced neovascularization in the chick chorioallantoic membrane assay and a rabbit hind-limb ischemia model [7].

Nucleic-acid binding and innate immune sensing

A 2007 study reported that LL-37 binds self-DNA into aggregated, condensed structures that are taken up by plasmacytoid dendritic cells and retained in early endosomes, where they trigger Toll-like receptor 9 and type I interferon production. The authors identified this as a pathway that may drive autoimmunity in psoriasis [8].

Areas of research

Antimicrobial and antibiofilm research

In a 2008 in vitro study with Pseudomonas aeruginosa, LL-37 inhibited biofilm formation at concentrations far below those needed to kill or inhibit bacterial growth. It also affected pre-grown biofilms. The authors linked this to reduced bacterial attachment, increased twitching motility, and down-regulation of the Las and Rhl quorum-sensing systems [6].

Epithelial repair models

In a 2005 study using the NCI-H292 airway epithelial cell line and differentiated primary airway epithelium, LL-37 stimulated closure of mechanically induced wounds in cell monolayers and induced proliferation and migration of NCI-H292 cells. The effect depended on the presence of serum, and inhibitor experiments implicated the epidermal growth factor receptor, a G protein-coupled receptor, and MAP/ERK kinase signaling [18].

Wound and vascular models

The angiogenesis study above also reported reduced vascularization during wound repair in mice lacking CRAMP, the mouse counterpart of LL-37, which the authors took as evidence that cathelicidin-mediated angiogenesis matters for skin wound neovascularization in that model [7].

Autoimmunity and inflammation

Because LL-37 can convert self-DNA into an interferon trigger [8], it is studied as a possible contributor to inflammatory skin disease, not only as a defense molecule. A 2024 review of LL-37 and nucleic-acid complexes described both sides of this literature: immunostimulatory effects considered useful in host defense, and evidence that the same complexes may contribute to autoimmune conditions such as psoriasis and systemic lupus erythematosus. The authors called for structural work on how nucleic acids are condensed within these complexes to explain the contradictory findings [19]. This is one of several reasons researchers describe LL-37 activity as context-dependent.

Cancer research

Reviews describe opposing effects of LL-37 in cancer models depending on tissue. A 2016 review reported that LL-37 overexpression was found to promote development and progression of ovarian, lung, and breast cancers and to suppress tumorigenesis in colon and gastric cancer, and attributed these differences to the different membrane receptors expressed by different cancer cells [10]. A 2018 review listed tumor-promoting effects in further cancer types, including prostate, pancreas, and melanoma, and anti-cancer effects in others, including hematologic malignancy [11].

Choosing a model system

Species differences matter for LL-37 work. The mouse counterpart, CRAMP, shares about 67% identity with LL-37 and did not inhibit biofilm formation at subinhibitory concentrations in the 2008 Pseudomonas study [6], and the vitamin D control of the human gene is not conserved in mice [17]. Study designs that move between human cells and rodent models need to account for these differences.

Open research questions

  • Which receptor mediates which effect in a given tissue, since several membrane receptors have been implicated [10].
  • Whether shorter fragments, such as KR-12, which was selectively toxic to bacteria over human cells in one study [5], can retain antimicrobial activity with less host-cell signaling.
  • How results with exogenous peptide relate to endogenous LL-37 released from hCAP-18 at sites of inflammation [4].

State of the human evidence

Clinical testing of LL-37 has been limited to a topical formulation studied in hard-to-heal venous leg ulcers, developed under the nonproprietary name ropocamptide [13].

  • A first-in-human, randomized, placebo-controlled trial published in 2014 included 34 participants. The authors reported no local or systemic safety concerns and called for further investigation [12].
  • A larger multicentre, randomized, placebo-controlled phase IIb trial of 148 patients, published in 2021, did not identify a significant difference in healing between LL-37 and placebo across the full study population. The authors also reported a post hoc subgroup analysis in participants with large wounds, which is exploratory rather than confirmatory, and proposed a further study [13].

No LL-37 product is FDA approved. The clinical data concern one topical formulation in one condition, and they do not establish safety or efficacy for any other form or use. Findings from cell and animal models should not be read as evidence of safety or benefit in people.

Regulatory status

  • Not FDA approved. We found no FDA-approved drug containing LL-37 (cathelicidin) in Drugs@FDA (checked October 12, 2026) [16].
  • FDA safety-risks page. FDA's page of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) lists cathelicidin LL-37 among substances whose nominations were withdrawn by the nominators. Its entry states that compounded drugs containing it may pose a risk of immunogenicity for certain routes of administration and may have complexities with peptide-related impurities and API characterization, that FDA lacks sufficient safety information to know whether it would cause harm in humans, and that nonclinical findings suggest detrimental effects on male reproduction and that it can be protumorigenic in some tissues [14].
  • Advisory committee. FDA's Pharmacy Compounding Advisory Committee meeting page (content current as of April 15, 2026) lists cathelicidin (LL-37) among substances to be discussed for possible inclusion on the 503A bulks list, at a meeting FDA says it will hold before the end of February 2027. No date had been announced on that page when we checked [15].

Rejuvatide supplies LL-37 strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

A lot-specific certificate of analysis for LL-37 is not yet hosted on this page. You can request the certificate for your lot through our COA library, and certificates are supplied exactly as the laboratory issued them.

LL-37 is unrelated to KPV, a different peptide in our catalog. Browse all immune and cellular research peptides.

Storage of lyophilized material

LL-37 ships as a lyophilized (freeze-dried) powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

LL-37 FAQ

What is LL-37?

LL-37 is a 37-amino-acid peptide released from the human cathelicidin protein hCAP-18. It is the only human cathelicidin-derived antimicrobial peptide and is studied in antimicrobial, immune-signaling, and wound-model research.

How is LL-37 generated from its precursor?

It is cut from the C-terminal end of hCAP-18. A 2001 study of human neutrophils found that the protease proteinase 3 performs this cleavage after the precursor is released from the cell.

Is LL-37 FDA approved?

No. A topical LL-37 formulation has been tested in small clinical trials for venous leg ulcers, but no LL-37 product is FDA approved. FDA has said its compounding advisory committee will discuss LL-37 before the end of February 2027.

Why do researchers describe LL-37 as double-edged?

Published studies report protective activities, such as antimicrobial and antibiofilm effects, alongside activities linked to harm in some models, including triggering interferon responses to self-DNA and promoting tumor growth in certain tissues.

What size does Rejuvatide offer?

LL-37 is available as a 5mg vial of lyophilized powder.

Is LL-37 for human use?

No. Rejuvatide sells LL-37 for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. LL-37, Compound CID 16198951. National Library of Medicine. Source
  2. UniProt. P49913, Cathelicidin antimicrobial peptide (CAMP), Homo sapiens. Peptide LL-37, residues 134-170. Source
  3. Dürr UH, Sudheendra US, Ramamoorthy A. Biochim Biophys Acta. 2006;1758(9):1408-25. PubMed 16716248
  4. Sørensen OE, Follin P, Johnsen AH, et al. Blood. 2001;97(12):3951-9. PubMed 11389039
  5. Wang G. J Biol Chem. 2008;283(47):32637-43. PubMed 18818205
  6. Overhage J, Campisano A, Bains M, et al. Infect Immun. 2008;76(9):4176-82. PubMed 18591225
  7. Koczulla R, von Degenfeld G, Kupatt C, et al. J Clin Invest. 2003;111(11):1665-72. PubMed 12782669
  8. Lande R, Gregorio J, Facchinetti V, et al. Nature. 2007;449(7162):564-9. PubMed 17873860
  9. Wang TT, Nestel FP, Bourdeau V, et al. J Immunol. 2004;173(5):2909-12. PubMed 15322146
  10. Piktel E, Niemirowicz K, Wnorowska U, et al. Arch Immunol Ther Exp (Warsz). 2016;64(1):33-46. PubMed 26395996
  11. Chen X, Zou X, Qi G, et al. Cell Physiol Biochem. 2018;47(3):1060-1073. PubMed 29843147
  12. Grönberg A, Mahlapuu M, Ståhle M, et al. Wound Repair Regen. 2014;22(5):613-21. PubMed 25041740
  13. Mahlapuu M, Sidorowicz A, Mikosinski J, et al. Wound Repair Regen. 2021;29(6):938-950. PubMed 34687253
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee (content current as of April 15, 2026). Source
  16. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs database (searched October 12, 2026). Source
  17. Gombart AF, Borregaard N, Koeffler HP. FASEB J. 2005;19(9):1067-77. PubMed 15985530
  18. Shaykhiev R, Beisswenger C, Kändler K, et al. Am J Physiol Lung Cell Mol Physiol. 2005;289(5):L842-8. PubMed 15964896
  19. Zielke C, Nielsen JE, Lin JS, et al. Biophys J. 2024;123(11):1316-1328. PubMed 37919905